Zhuhai Kinhoo Pharmaceutical Co. Ltd.

Primary objective: To compare the differences in the absorption extent and absorption rate of loxoprofen sodium patch (100 mg/patch (10 cm×14 cm)) provided by Jinhong Pharmaceutical Co., Ltd. and loxoprofen sodium patch (specification: 100 mg/patch (10 cm×14 cm)) certified by Lead Chemical Co., Ltd. in Chinese healthy population under fasting administration conditions using a single-center, randomized, open, two-drug, two-period crossover, fasting trial design, and evaluate bioequivalence. Secondary objectives: 1) To evaluate the safety of the test preparation and the reference preparation in Chinese healthy subjects; 2) To evaluate the adhesion of the test preparation and the reference preparation during medication in Chinese healthy subjects; 3) To evaluate the skin reactivity of the test preparation and the reference preparation in Chinese healthy subjects.

Main study objectives: To evaluate the pharmacokinetic characteristics and bioequivalence of the test formulation of ibrutinib capsules (specification: 0.14g, applicant: Jinhong Pharmaceutical Co., Ltd.) and the reference formulation (trade name: Yike®, specification: 140mg, licensee: Janssen-Cilag International NV) after a single oral dose under fasting conditions in healthy Chinese adult subjects. Secondary study objectives: To study the safety of the test formulation of ibrutinib capsules (specification: 0.14g) and the reference formulation (trade name: Yike®, specification: 140mg) in healthy Chinese adult subjects.

Main study objectives: To evaluate the pharmacokinetic characteristics and bioequivalence of the test formulation of ibrutinib capsules (specification: 0.14g, applicant: Jinhong Pharmaceutical Co., Ltd.) and the reference formulation (trade name: Yike®, specification: 140mg, licensee: Janssen-Cilag International NV) after a single oral dose under postprandial conditions in healthy Chinese adult subjects. Secondary study objectives: To study the safety of the test formulation of ibrutinib capsules (specification: 0.14g) and the reference formulation (trade name: Yike®, specification: 140mg) in healthy Chinese adult subjects.